An Open Label Extension Study to Assess the Safety of Long-Term Treatment With a 4 mL Intra-Articular Injection of Ampion in Adults With Pain Due to Severe Osteoarthritis of the Knee

Trial Profile

An Open Label Extension Study to Assess the Safety of Long-Term Treatment With a 4 mL Intra-Articular Injection of Ampion in Adults With Pain Due to Severe Osteoarthritis of the Knee

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs DMI 9523 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Registrational
  • Sponsors Ampio Pharmaceuticals
  • Most Recent Events

    • 22 Nov 2017 New trial record
    • 15 Nov 2017 According to an Ampio media release, this OLE study will address the regulatory requirements to allow an expanded commercial label for repeat administration of Ampion™.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top